Hypothesis\n\nIf gut‑derived uremic toxins and TMAO are primary drivers of endothelial senescence, then a synbiotic formulation that selectively suppresses their production while boosting SCFA‑mediated AhR activation will reduce arterial stiffness (PWV) in older adults without requiring central nervous system modulation.\n\n## Rationale\n\nRecent work shows that dysbiosis‑derived metabolites such as TMAO, p‑cresyl sulfate and indoxyl sulfate enter the circulation ahead of systemic inflammation and directly impair endothelial NO production, promote oxidative stress via NADPH oxidase/NLRP3, and drive calcification[https://pmc.ncbi.nlm.nih.gov/articles/PMC12072866/][https://pubmed.ncbi.nlm.nih.gov/31159610/][https://www.tandfonline.com/doi/full/10.1080/0886022X.2024.2435485]. Conversely, SCFAs from fiber fermentation enhance NO bioavailability and protect against oxidative stress[https://pmc.ncbi.nlm.nih.gov/articles/PMC6864778/].\n\n## Mechanistic Extension\n\nBeyond the classic NO/ROS balance, we propose that aryl hydrocarbon receptor (AhR) activation by bacterial tryptophan metabolites (e.g., indole‑3‑propionic acid) acts as a molecular switch that shifts endothelial cells from a senescent to a protective phenotype. AhR ligands induce expression of Nrf2‑dependent antioxidant enzymes and suppress NF‑κB signaling, thereby counteracting TMAO‑induced oxidative burst[https://pmc.ncbi.nlm.nih.gov/articles/PMC9414425/][https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2024.1491731/full]. A synbiotic that (i) supplies precise prebiotic fibers favoring SCFA‑producing Faecalibacterium and Roseburia spp., (ii) delivers a probiotic strain engineered to express tryptophan‑lyase for increased indole‑3‑propionic acid, and (iii) incorporates a bacteriophage or bacteriocin that selectively reduces Cutibacterium‑derived TMAO precursors, should simultaneously lower toxic metabolites and raise AhR‑activating ligands.\n\n## Predictions\n\n- Primary: 12‑week intervention will produce a ≥10 % reduction in carotid‑femoral PWV compared with placebo (p < 0.01).\n- Secondary: Plasma TMAO and p‑cresyl sulfate will decrease ≥20 %; fecal SCFA and indole‑3‑propionic acid will increase ≥30 %; circulating Nrf2 target gene expression in peripheral mononuclear cells will rise.\n- Exploratory: No significant change in central autonomic markers (heart‑rate variability, cortisol) will be observed, supporting a gut‑to‑vessel direction of effect.\n\n## Experimental Design\n\nA double‑blind, placebo‑controlled trial in 200 participants aged 60‑80 with baseline PWV > 10 m/s. Randomization to synbiotic vs. iso‑caloric maltodextrin placebo. Primary endpoint: change in PWV at week 12. Secondary endpoints: metabolomics (LC‑MS) for TMAO, p‑cresyl sulfate, SCFAs, indole‑3‑propionic acid; flow‑mediated dilation; endothelial progenitor cell count; salivary cortisol and HRV. Intention‑to‑treat analysis.\n\n## Potential Confounds & Controls\n\nDietary fiber intake will be standardized via run‑in food logs and supplemental low‑fiber baseline diet. Antibiotic use excluded within 3 months. Medications affecting endothelium (statins, ACE inhibitors) recorded and balanced across groups.\n\n## Falsifiability\n\nIf the synbiotic fails to lower PWV despite achieving the predicted metabolite shifts, or if PWV improvement correlates tightly with changes in HRV/cortisol rather than metabolite levels, the hypothesis that gut‑derived signals are upstream drivers of vascular aging would be refuted, favoring a top‑down CNS‑gut model.